** Shares of medical device maker ResMed RMD.N fall 3.8% to $244.56
** RMD's rival Apnimed said late on Monday that its oral pill met the main goal in a late-stage study to treat obstructive sleep apnea
** Apnimed's experimental drug, AD109, showed a mean reduction of 55.1% on a scale that measures mild, moderate and severe obstructive sleep apnea
** Apnimed says the drug significantly improved oxygenation and reduced disease severity in patients
** It plans to submit a marketing application to the U.S. FDA for the drug, AD109, by early 2026
** ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep
** Including session's moves, RMD up 10.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.